Aristaless-related genes encode a structurally defined group of homeoproteins that share a C-terminal stretch of amino acids known as the OAR-or aristaless domain. Many aristaless-related genes have been linked to major developmental functions, but the function of the aristaless domain itself is poorly understood. Expression and functional studies have shown that a subgroup of these genes, including Prx1, Prx2, Alx3, Alx4 and Cart1, is essential for correct morphogenesis of the limbs and cranium. We now demonstrate the function of the aristaless domain in vivo by ectopically expressing normal and mutated forms of Cart1 and Alx3. Ectopic expression of Cart1 in transgenic mice does not disturb development, whereas expression of a Cart1 form from which the aristaless domain has been deleted results in severe cranial and vertebral malformations. The Alx3 protein contains a divergent aristaless domain that appears not to be functional, as ectopic expression of Alx3 results in an altered phenotype irrespective of the presence of this aristaless domain. Linking the Cart1 aristaless domain to Alx3 extinguishes teratogenicity. We show that, at the molecular level, the most important consequence of deleting the aristaless domain is increased DNA binding to its palindromic target sequence. This demonstrates that the aristaless domain functions as an intra-molecular switch to contain the activity of the transcription factor that it is part of. q
Introduction
A subset of the large class of Paired-class homeoproteins contains a conserved C-terminal amino acid stretch known as the OAR or aristaless domain (Simeone et al., 1994; Galliot et al., 1999;  Table 1 ). We have distinguished three subgroups of aristaless-related genes, each involved in apparently different biological processes (Meijlink et al., 1999) . The biochemical properties presumably shared by these proteins suggest their involvement in similar interand intra-molecular interactions.
Our research is focused on the subgroup of genes consisting of Alx3, Alx4, Cart1 and the Prx genes ('Group-I aristaless-like genes'; Meijlink et al., 1999) , which are characteristically expressed during embryogenesis in mesenchyme of craniofacial primordia and limb buds. We and others have reported defects in skeletal elements and their embryonic precursors in mice and embryos carrying loss-of-function (LOF) mutations in these genes. The group-I genes have thus been linked to specific early functions in growth and morphogenesis of particularly craniofacial and appendicular structures. Due to redundant gene functions, full appreciation of these phenotypes requires analysis of double mutants (Ten Berge et al., 1998b; Lu et al., 1999a,b; Qu et al., 1999; . The mechanistic basis of some of these defects has been linked to epithelio-mesenchymal interactions (Ten Berge et al., 2001 ) and anomalous apoptosis .
The aristaless domain is likely to have a similar molecular function in all aristaless-related proteins, but this function is only partly understood. A function as activation domain in the Otp protein was proposed originally (Simeone et al., 1994) , but more recent studies in vitro have suggested that the aristaless domain functions to attenuate transcriptional activation (Amendt et al., 1999; Norris and Kern, 2001) .
The specific developmental expression patterns of Alx3, Alx4 and Cart1 (Zhao et al., 1993; Ten Berge et al., 1998a; ) in craniofacial and appendicular structures suggest that these genes provide positional cues during embryogenesis, and that defects associated with ectopic expression of these proteins could be instructive as to their biological functions. Therefore, and as an approach complementary to our LOF analyses, we ectopically expressed Alx3 using the modified Hox enhancer, (BH1100) 4 . This enhancer/promoter combination drives gene expression in mandibular ectomesenchyme and in posterior mesoderm of the fore limb buds, in addition to a typical Hox pattern in paraxial mesoderm and neural tube (Charité et al., 1995) . A significant proportion of the embryos in which Alx3 was overexpressed suffered from skeletal abnormalities in vertebrae, craniofacial skeleton, body wall and shoulder girdle. We then used this phenotype as a read-out in experiments aimed at investigating the role of the aristaless domain in Alx3 and Cart1. This analysis provides for the first time in vivo evidence that the normal function of the aristaless domain is to attenuate the transcriptional activation potential of aristaless domain proteins, and that its deletion can turn the Cart1 protein into a dysmorphogenic protein. Our results suggest that at the molecular level above all the DNA binding properties are affected by deletion of the aristaless domain. They also indicate that the unusual aristaless domain of Alx3 is a degenerated version that has lost most or all of its function.
Results

Ectopic Alx3 expression
We expressed the Alx3 gene in transgenic embryos using construct BA3 (see Fig. 1A ,B). In this construct expression is under control of a promoter-enhancer combination designated (BH1100) 4 (Charité et al., 1995;  abbreviated to 'B' in our construct names) which consists of the normal Hoxb8 promoter and flanking sequences linked to four tandem copies of a 1.1 kb BamHI-HindIII fragment that is located about 3.5 kb upstream from the Hoxb8 promoter (Fig. 1A) . Charité et al. (1995) have shown that a lacZ reporter gene linked to this cassette is expressed at the 16-somite stage in an antero-posterior Hox-pattern in somitic mesoderm up to somite 11 and in the neural tube with a sharp anterior border adjacent to somites 5/6 ( Fig. 2A) . In addition it drives expression in posterior mesoderm of the forelimb bud as shown for embryonic day (E) 10.5 in Fig. 2B , and in neural crest derived mesenchyme of the mandibular arch ( Fig. 2A) . The main differences between the expression patterns of (BH1100) 4 (Charité et al., 1995) and Alx3 (Ten Berge et al., 1998a; ) are: (1) Alx3 is not expressed in dorsal structures like neural tube and adjacent mesoderm, except for lateral plate mesoderm extending into the anterior part of the limb buds; (2) in the developing craniofacial region Alx3 expression is normally confined to the distal parts of the mandibular processes, whereas a (BH1100) 4 lacZ is expressed throughout the neural-crest derived mandibular mesenchyme; (3) Alx3 is expressed anteriorly in limb bud mesoderm, whereas the (BH1100) 4 promoter drives expression in mesoderm posteriorly in the fore limb bud and both anteriorly and posteriorly in the hind limb bud.
Alx3 gain-of-function leads to skeletal defects
All analyses were done in F 0 embryos or newborns, each representing an independent DNA integration. We isolated 21 transgenic embryos and newborns carrying construct BA3 (Fig. 1A ,B) at stages from embryonic day (E) 14.5 to birth and analysed them by skeletal staining. Of 21 embryos and newborns shown by PCR to be transgenic, 11 had visible skeletal and other abnormalities that were never seen in control littermates. The relatively frequent (approx. 50%) absence and high variability in severity, but not the nature, of the phenotypes is likely due to effects of the genomic integration sites of the expression construct and is similar to that observed for transgenic experiments in general and the corresponding lacZ reporter construct in particular.
Those embryos that were immediately most conspicuously affected had a shortened and wider neck region, an abnormally curved tail and in several cases gastroschesis (see Fig. 2C ). Skeletal analyses of these animals (e.g. Fig.  3A ) as well as of many other transgenic foetuses that appeared superficially normal, demonstrated specific skeletal defects. In spite of the variability in strength of these defects they were qualitatively similar. Affected structures were seen in the vertebral column, the craniofacial region and in the shoulder girdle (see Figs. 2-4).
Craniofacial (Fig. 2D-G)
Craniofacial abnormalities were seen in many affected embryos and newborns, but the severity of the phenotypes was highly variable. Clearly the overexpression of Alx3 disorganized the mandibular arch in such a way that many neural crest derived bones were malformed. In the subtle Table 1 Unusual composition of the Alx3 aristaless domain: OAR/aristaless domains of aristaless and 16 mammalian homeodomain proteins
processes underlying cranial development in which tissue interactions and organized outgrowth are central, it seems likely that limited differences in strength of expression can have major effects. Most of the mandibular and maxillary bones looked distorted and the shape of the head was often stubby. The mandible looked shortened and broadened (in anterior-posterior direction), as shown in Fig. 2E of a newborn. More dorsal structures that are not neural crest derived, like the basisphenoid, appeared normal. Ectopic cartilages were frequently observed in the stronger phenotypes; in two embryos these appeared to be a duplication of Meckel's cartilage (see Fig. 2G ).
Axial skeleton (Fig. 3)
The vertebrae were strongly reduced in size and malformed in the stronger phenotypes (Fig. 3A,A  0 ). In the weaker phenotypes ( Fig. 3C ) it appeared that the vertebrae were partially fused (Fig. 3C ). The vertebrae most strongly affected were those around the cervical to thoracic transition ( Fig. 3B-D) , which originate from the somites in the region where the anterior border of the (BH1100) 4 lacZ expression at E10.5 was localized by Charité et al. (1995) . The ribs were truncated or even absent at positions where the vertebrae were affected (see for instance Fig. 3D ); the sternum was also absent or highly abnormal, apparently as a consequence of the abnormal ribs.
Shoulder girdle (Fig. 4A,B)
While the original rationale of the experiment was to produce a mirror image of the anterior expression of Alx3 in the limb bud, the anticipated distal abnormalities in the limbs were never seen in embryos carrying construct BA3. An ectopic process was in many cases present on the posterior aspect of the scapula, bending out of the plane of the scapula towards the midline (Fig. 4B ).
Absence of malformations in embryos overexpressing Cart1
Cart1 was ectopically expressed using a construct of the same configuration (construct BC1, Fig. 1A ,B). Of 13 transgenic foetuses, the phenotype of 11 was not affected and two had weak abnormalities of the cervical vertebrae, as well as an ectopic process on the scapula, very similar to the weakest phenotypes obtained with the BA3 construct. The higher teratogenicity of Alx3 stands out against studies of LOF mutants of Cart1 (Zhao et al., 1996) and Alx3 ) that indicate a higher functional impact of Cart1. Since Alx3 and Cart1 share near -identical paired-type homeodomains, they are likely to regulate the same direct target genes, and different parts of the protein should therefore be responsible for the difference in dysmorphogenic potential. The Alx3 aristaless domain is and strong phenotype (D) of vertebra/rib phenotype in E15.5 BA3 transgenic embryos. The cervical vertebrae are numbered to demonstrate that vertebra 7 is the first one affected. The orange braces indicate the same region in all three skeletons, also showing location of affected region. Note fused vertebrae in C. at, atlas; ax, axis; s, sternum; r, rib. highly unusual in that it carries three prolines, making it plausible that its function, whatever it is, is reduced (Table  1) . We therefore wondered what would be the impact of deleting the aristaless domain on Alx3 mediated teratogenicity.
The aristaless domain is not required for the Alx3 phenotype
We modified the construct used for ectopic expression of Alx 3 by introducing a stop codon directly in front of the aristaless domain. The protein encoded by construct BA3DAD therefore lacks only the aristaless domain and the seven more C-terminal amino acids. We defined the aristaless domain on the basis of sequence comparisons as a stretch of 16 amino acids (see Ten Berge et al., 1998a; Table 1 ). We analysed three transgenic foetuses carrying this construct, one of which was normal, while two showed the strong phenotype also seen for BA3. This demonstrates that the aristaless domain is not required for the GOF defects described above. Indeed, some of the strongest expressions of the phenotype were obtained with this construct, leaving open the possibility that activity is somewhat enhanced. This suggested that the aristaless domain may be functioning in a negative way. Such an attenuating function would explain why Alx3 with its presumably disabled aristaless domain would still be able to function as a transcriptional activator and it would also be consistent with the absence of an abnormal phenotype upon ectopic expression of Cart1. It would furthermore lead to the prediction that deletion of the aristaless domain of Cart1 would enhance the activity of this transcription factor. Two groups reported in vitro data that supported the notion that deletion of the aristaless domain unleashes the activity of the aristaless-related proteins, Pitx2 and Prx2, respectively (Amendt et al., 1999; Norris and Kern, 2001 ), but these studies did not address the issue in vivo.
Deletion of the aristaless domain from the Cart1 protein converts it to a teratogenic form
To investigate the possibility of an attenuating role of the aristaless domain of Cart1 we expressed a truncated Cart1 form using construct BC1DAD. Exactly as in construct BA3DAD, the Cart1 variant encoded by this construct lacks the 16-amino acid aristaless domain, as well as the 7-amino-acid C-terminus, leaving the remaining part of the protein intact. From a total of 14 transgenic foetuses, eight had skeletal malformations. Embryos with weak phenotypes (three) as well as those strongly affected (five) were morphologically very similar to those obtained with the BA3 and the BA3DAD constructs. This shows that deletion of the aristaless domain converts Cart1 into a protein with teratogenic properties and is consistent with the notion that the aristaless domain serves to attenuate the action of the aristaless-related proteins.
Cart1 aristaless domain represses teratogenicity of Alx3
To further challenge our working hypothesis regarding the attenuating function of the Cart1 aristaless domain, we asked whether replacing the aristaless domain of Alx3 with that of Cart1 (construct BA3ADC) could reduce the teratogenicity of the Alx3 protein. Analysis of 7 transgenic foetuses carrying this construct confirmed to a large extent the prediction that a non-teratogenic protein would result. Five transgenic foetuses were normal and in two the ectopic scapula process was seen (as in Fig. 4B ). This experiment demonstrates that activity of the Alx3 protein is greatly reduced when a 'regular' aristaless domain replaces its own disabled one. Surprisingly, one extra digit was seen in hind limbs of the same two embryos that have the minor shoulder phenotype (Fig. 4C ). This phenotype was not seen in any other of the embryos in this study. Since Alx4 LOF mutants have preaxial polydactyly (Forsthoefel, 1962; Qu et al., 1997) and Alx3 and Alx4 are likely to have the same targets, we interpret this result as evidence that the BA3ADC protein has dominant-negative properties in the context of distal limb mesoderm. Together our experiments (see Table 2 for an overview) demonstrate that the aristaless domain of Cart1 has a negatively modulating role in transactivation. 
a S, total number; No, no visible abnormalities; Weak, relatively minor abnormalities; Strong, defects and reductions making skeletal elements unrecognizable or non-existent. b 1 , affected; 2, not affected; 1 /2, minor abnormalities.
Impact of aristaless domain-mutations on transcriptional activity
To further investigate the molecular basis of the GOF phenotype caused by ectopic expression of aristaless-related homeodomain proteins we designed an assay to serve as in vitro read-out for transcriptional activity of the Alx3/Cart1 protein variants. It is known that paired type homeodomain proteins bind as dimers to palindromic target sequences (Wilson et al., 1995) . This has been confirmed (Wilson et al., 1996) and further investigated for Alx4 by Qu et al. (1999) . Based on these data we made a DNA-construct consisting of the luciferase reporter gene driven by three tandemly repeated P3 sites (TAATCCGATTA) linked to a minimal E1B reporter (Fig. 1C) . In a second type of reporter construct three P5 sites (TAATCCGGGATTA) replaced the P3 sites. We co-transfected these reporter constructs into P19 EC cells, together with expression constructs based on the pSG5 vector that produced the same normal or mutated forms of Alx3 and Cart1 that were used in the in vivo experiments, under control of the SV40 early promoter (constructs SGA3, SGA3DAD etc.; see Fig. 1D . As expected, (Wilson et al., 1996; Qu et al., 1999) only with the P3 constructs did we observe significant activation of the reporter gene. The results (Fig. 5) show a clear correlation of transcriptional activity in transfected cells and the teratogenic potential of the same protein form in transgenic foetuses. Construct SGA3 has much more activity than SGC1, while removal of the aristaless domain (construct SGC1DAD) activates Cart1 as a transcriptional activator in this experimental context. On the other hand Alx3 was, at most, marginally activated by deletion of its aristaless domain, while luciferase activation by the hybrid Alx3-Cart1 protein was strongly decreased compared to that of the normal Alx3 protein.
Impact of aristaless domain-mutations on DNA binding
The differences in transcriptional activation by the various proteins can in principle be explained either by the aristaless domain directly affecting transactivation, or by effects on the DNA binding properties of the protein.
To make this distinction, we complemented our transactivation studies with electrophoretic mobility shift assays. The expression constructs used in the cell transfection experiments described above were now transfected in COS-cells, where they are expected to be highly amplified due to the presence of the SV40 origin of replication, and cell extracts were prepared from these cells. 32 P-Labelled oligonucleotides representing the P3 and P5 sites that mediated the transactivation in the luciferase assays were used as probes. We never detected any shift of the P5-oligo probe with extracts from cells transfected with the Alx/Cart constructs, whereas we obtained a strong shift with a similar extract containing Pitx2 protein (not shown). The latter result served as a positive control for the quality of the P5 probe Fig. 5 . Activation of an artificial target construct is enhanced by deletion of the aristaless domain. Transient cotransfections of P19 cells were done as described in Section 4 and included 1.2 mg reporter construct, 1.2 mg expression construct and 0.6 mg pSV2lacZ. Luciferase measurements were corrected for differences in efficiency of transfection by normalization to b-galactosidase activity. The activities are shown as mean fold activations compared to that of P3-luciferase activity observed using the pSG5 vector instead of an expression construct. The result for SGC1 was based on eight experiments, that of SGC1DAD and SGA3DAD on seven, that of SGC1 on eight and that of SGA3C1AD on seven, where each experiment represents measurements in triplo of one calcium phosphate precipitate distributed over three plates. Error bars indicate standard error of the mean. and confirms the conclusions drawn by Wilson et al. (1996) : Paired/K50 homeodomain proteins like Pitx bind efficiently as monomers to sites containing so-called bicoid-binding sites TAATCC, as opposed to strong preference for dimeric binding by Q50 homeodomains. Binding to the P3 probe is therefore a useful read-out for efficiency of DNA binding of our set of Alx/Cart protein variants. As shown in Fig. 6 , specific binding was only detected with those protein forms that cause morphological alterations in vivo, i.e. C1DAD, Alx3 (A3) and A3DAD.
Discussion
The aristaless domain restrains the activity of aristaless-related transcription factors
The main conclusion from our results is that the aristaless domain of Cart1 functions to restrain activity of this transcription factor in vivo, mainly or completely through its effect on DNA binding. We show that deletion of the aristaless domain from the Cart1 protein unleashes its teratogenic potential. The Alx3 protein is already teratogenic when ectopically expressed in its normal form in the same expression pattern, and deletion of its aristaless domain increases its activity at most marginally. This result and the observation that the Alx3 aristaless domain has a very uncommon primary structure (Table 1) opens the possibility that the Alx3 aristaless domain is a molecular rudiment that has lost its function during recent evolution, comparable, for instance, to the homeodomains of Pax2 and Pax8 (Gruss and Walther, 1992) . We have reported earlier (Ten Berge et al., 1998a ) that the Alx3 protein sequence has diverged in a very non-random way from those of the related Cart1 and Alx4 proteins, in that it has a high proline content throughout the protein (except for the homeodomain). This may limit the activity of Alx3 and prevent it from being teratogenic in its normal expression domain. The fact that Alx3 teratogenicity is reduced by linking it to the Cart1 aristaless domain shows that a regular aristaless domain nevertheless can function in the diverged Alx3 protein. More importantly, it confirms the attenuating molecular role of this protein domain. It is interesting that at least in two cases an aristaless-related homeobox gene encodes, through alternative splicing, protein forms with and without an aristaless domain, namely Prx1 Kern et al., 1992 and SHOX (Rao et al., 1997) . It is conceivable that in those cases splicing regulates the ratio between constitutively active positive and more neutral forms of the same transcription factor. That deletion of a protein domain activates a transcription factor is not without precedent. Deletion of a carboxy-terminal domain from Nkx2.5 also leads to its activation (Chen and Schwartz, 1995; Durocher et al., 1997) . This deletion would unmask an activation domain and would thus mimic an in vivo unfolding caused by, in this case, an interaction with GATA-4. However no increased DNA binding ( Fig. 6 ; see below) would be involved.
The aristaless domain serves as an intramolecular switch
The exclusive presence of the aristaless domain in a subset of Paired-like homeodomain proteins, and its consistently C-terminal location suggest that it has a molecular function that is inherently and directly related to the way these homeoproteins exert their function. Amendt et al. (1999) ; Norris and Kern (2001) have previously published evidence based on work in vitro showing that deletion of the aristaless domain of other members of the aristaless-related protein family leads to transcriptional activation. These authors presented models proposing that intramolecular interactions between the aristaless domain and the N-terminus in the Pitx and Prx aristaless-related proteins lead to a protein conformation associated with a relatively inactive state of these transcription factors. Conceivably, intermolecular interactions in vivo would unfold the protein leading to its activation, and Amendt et al. present evidence from in vitro studies that Pit1 could have such a modulating role in the case of Pitx2 by direct interaction with its C-terminal region. Experimentally, the consequences of this intermolecular interaction would be mimicked by truncations and other modifications of the protein, since this could also impede the intramolecular interaction (see Amendt et al. (1999) and below). Strikingly, Norris and Kern (2001) showed that the results of truncation of the Prx2 protein strongly depended on the choice of cell line used. This (0) or with an amount of nuclear extract corresponding to 3, 6 or 12 mg protein (increasing amounts indicated by triangles). pSG5 indicates a nuclear construct in which only the empty vector was amplified, otherwise the protein forms expressed (using the SG-plasmids) are indicated. 'P3' indicates the free migrating band corresponding to the P3 probe.
demonstrates the importance of investigating these effects in the cells where they normally exert their function, i.e. in embryonic mesenchyme. Here we present for the first time the potential consequence in vivo of interfering with this supposed intramolecular interaction in an aristaless related homeoprotein.
Obviously, an important goal for future research will be the identification of the putative proteins that can unleash Cart1's activity through direct interaction. Candidates based on work in vitro include the Retinoblastoma and related proteins (Hudson et al., 1998) and Lef-1 (Hudson et al., 1998; Boras and Hamel, 2002) and, based on extrapolation of the work of Amendt et al. (1999) proteins that belong like Pit1 to the POU domain family.
The molecular basis of Cart1 activation
What is, mechanistically, the basis of aristaless-related gene activation through deletion of the aristaless domain? The model of Amendt et al. (1999) proposes effects both on the activation process itself and on DNA binding. In contrast, Norris and Kern (2001) did not find increased DNA binding as a consequence of deletion of the aristaless domain from the Prx2 protein, although they did for Nterminal truncations. Surprisingly, our data demonstrate an increased DNA binding of Cart1 lacking the aristaless domain, which is possibly sufficiently strong to account for the entire activation effect. One alternative explanation for the activation effect would be that the presence of the aristaless domain is associated with a lower stability of the protein. In the absence of specific antibodies that could measure the protein levels produced by the various constructs, it is not feasible to rule this out in a direct way. We therefore made fusion products in which a Myctag was linked to the N-terminal end of the Cart1 protein.
When this construct was tested in the transactivation assay, we noted that transcriptional activation by this protein form was essentially as high as the aristaless domain deleted form (unpublished data). It appears that the myc fusion induces an altered protein configuration, disrupting the supposed intramolecular interaction. While this thwarted our intentions to verify similar protein expression levels, it is interesting to note that a relatively mild modification of the N-terminus suffices to disrupt the putative intramolecular interaction involving the aristaless domain. While we cannot rule out that an intermolecular interaction underlies this activation, it is consistent with the suggestion of Amendt et al. and Norris and Kern that intramolecular interactions can also be disrupted by (in their case) deletions in the N-terminal part of the protein. On the other hand, Amendt et al. made similar fusion proteins of the Pitx2 protein that apparently were not activated. At any rate, the observation that modifications in two parts of the protein have similar effects on its activation is consistent with a crucial intramolecular interaction, while multiple intermolecular interactions remain possible.
Affected limb development
The expression in posterior mesoderm of the forelimb bud driven by the (BH100) 4 enhancer mirrors the normal Alx3 and Alx4 expression in anterior mesoderm of both limb buds. Alx4 loss-of-function mutants, and even more so Alx4/Cart1 double mutants, have preaxial polydactyly and frequently tibial and radial dysplasia (Forsthoefel, 1962; Qu et al., 1997 Qu et al., , 1999 , but our gain-of-function (GOF) approach did not interfere with normal development of the distal forelimb as only an ectopic process on the scapula was observed. Apparently ectopic posterior expression of Alx3 does not suffice to affect digit patterning in the limb, in line with the proposal of Te Welscher et al. (2002, in press ) that Alx4 functions downstream from factors like in particular Gli3 that set up the basic antero-posterior patterning of the limb field.
Significance
It is highly unlikely that the constructs that we used for ectopic expression encode proteins with a changed target specificity. In addition, the expression levels are of the same order of those of the normal genes, because of the nature of the promoters used and based on observations on embryos carrying a (BH100) 4 -LacZ construct. Therefore, quantitative and qualitative aspects of the GOF phenotype are rather close to the physiological situation, making it likely, although difficult to prove, that the developmental defects observed are caused by activation of the normal targets of Cart1. It seems therefore a reasonable assumption that the results described reflect a biologically significant process; and could be helpful in the search for targets of this and related genes. Finally the phenotypes described as well as the molecular nature of the mutations underlying them could help in identifying possibly occurring GOF mutations causing human birth defects in this group of genes that has already several times been linked to human disease through LOF mutations (Semina et al., 1996; Rao et al., 1997; Mavrogiannis et al., 2001; Stromme et al., 2002) .
Experimental procedures
Production and analysis of transgenic embryos
DNA fragments for microinjection were separated from vector sequences by SalI digestion, isolated from agarose gels using the Gene Clean Spin kit (BIO 101 Systems) and further purified by dialysis. The fragments were injected into CBA £ C57Bl/6J F 2 zygotes as described (Vogels et al., 1993) . Embryos were transferred to foster mothers and recovered at various stages. The presence of the transgene in yolk sac DNA was detected by rabbit b-globin specific PCR; the primers 5 0 -TGGGGACCCTTGATTGTTCTTT-3 0 and 5 0 -GGGCCCGGTTTGGACTC-3 0 produce a 525 bp fragment. Alcian Blue/Alizarin Red skeletal staining was done as described ). All animal experiments were conducted under the approval of the animal care committee of the KNAW (Royal Dutch Academy of Arts and Sciences).
Molecular cloning
The expression constructs used for transactivation experiments in P19 EC cells and for expression in COS-1 cells were based on the vector pSG5 (Stratagene) which contains an SV40 promoter and polyadenylation cassette, and bglobin intron and splice sites. To make SGA3, a 1.8 kb EcoRI-SspI mouse Alx3 cDNA fragment (Ten Berge et al., 1998a) was cloned into pSG5. The Alx3 aristaless domain (AD) was deleted by site-directed mutagenesis (QuikChange site-directed mutagenesis kit, Stratagene). Nucleotides A and C in position 1110 and 1111 of the Alx3 cDNA were replaced by one G, creating an in-frame stop codon and a frameshift directly upstream of the aristaless domain. An extra PshAI site upstream of the Alx3 AD was thereby created in the resulting construct SGA3DAD. For substitution of the Alx3 AD by that of Cart1, a 74-mer oligonucleotide, containing the sequence of the Cart1 aristaless domain and the 7 C-terminal amino acids of Alx3, was inserted in the PshAI site of SG5A3DAD, resulting in construct SGA3ADC. For construct SG5C1 a 1.7 kb XhoI rat Cart1 cDNA fragment (a kind gift of B. de Crombrugghe, Houston, TX, USA) was cloned into pSG5. The deletion of the Cart1 aristaless domain was done by site directed mutagenesis. G in position 1364 was changed to TA, which created a stop codon and a frameshift directly upstream of the AD, resulting in construct SGC1DAD.
The in vivo expression constructs were based on p(BH1100) 4 lacZ (Charité et al., 1995) . In our terminology (BH1100) 4 is abbreviated to B. For BA3 a StuI-XbaI fragment was isolated from SG5A3 containing the rabbit b-globin intron and splice sites, the Alx3 cDNA and the SV40 polyadenylation signal, and cloned into p(BH1100) 4 -lacZ, replacing a BglII-NotI fragment that contains the lacZ cDNA and the polyadenylation signal. This resulted in a construct in which Alx3 was driven by a Hoxb8 promoter fragment and four copies of the BH1100 enhancer. To make BA3DAD and BA3ADC, the 1.6 kb NotI-BglII fragment from BA3 containing the Alx3 cDNA was replaced by corresponding fragments from SGA3DAD and SGA3ADC, respectively. Similarly, BC1 and BC1DAD were made by replacing the coding sequence of BA3 by 1 kb RsaI-SmaI Cart1 cDNA fragments from SG5C1 and SG5C1DAD, respectively.
The luciferase reporter constructs 3P3E1bluc and 3P5E1bluc were generated by introducing the fragment (upper strand) 5 0 -AGCTTAGAATAATCCGATTACTGT-ACACCTGAGAATAATCCGATTACTGTACACCTGA-GAATAATCCGATTACTG-3 0 and 5 0 -AGCTTAGAAT-AATCCGGGATTACTGTACACCTGAGAATAATCCG-GGATTACTGTACACCTGAGAATAATCCGGGATTA-CTG-3 0 , respectively, in the reporter construct E1bluc
(made by R. de Jong); this reporter construct consists of an E1b TATA-box containing promoter inserted in the P19-luciferase vector (van Zonneveld et al., 1988) . The fragments were made by annealing synthetic oligonucleotides (Isogen).
Cell culture procedures
P19 EC and COS-1 cells were cultured as monolayers on gelatine-coated (for P19) dishes in DMEM/F-12 Nutrient Mix 1:1 supplemented by 7.5% (v/v) foetal calf serum (FCS) at 37 8C and 7.5% CO 2 . For transient transfection assays in P19 EC cells 7:5 £ 10 3 cells/cm 2 were cultured in 12-well plates. Twenty-four hours after plating the cells were transfected by the calcium phosphate co-precipitation method with 1.2 mg luciferase reporter plasmid, 1.2 mg pSG5 expression plasmid and 0.6 mg pSV2lacZ as an internal control. After 18 h the precipitate was removed and cells were cultured for another 24 h and then collected and used for quantification of b-galactosidase and luciferase activities.
Reporter assays
Cells were lysed on plate in 200 ml Triton-lysis buffer, pH 7.8 (1% Triton X-100, 25 mM glycylglycin, 15 mM MgSO 4 , 4 mM EGTA) for 20 min at 4 8C. Lysates were used directly for assaying luciferase activity using the LucLite Luciferase Gene reporter assay kit (Packard), according to the manufacturer's protocol, in a Topcount liquid scintillation counter (Packard). Values were corrected for transfection efficiency by measuring b-galactosidase activity: 50 ml lysate was added to 100 ml lysis buffer and 90 ml b-galactosidase substrate (1.8 mg/ml o-nitrophenyl b-d-galactopyranoside in buffer containing 120 mM Na 2 HPO 4 , 100 mM NaH 2 PO 4 , 30 mM KCl, 3 mM MgSO 4 and 15 mM bmercaptoethanol) in 96-well microtiter plates. Reactions were incubated for 1-2 h at 37 8C in the dark and activity was measured at l ¼ 420 nm in a microplate reader (BioRad).
Electrophoretic mobility shift assay (EMSA)
For nuclear extracts COS-1 cells were grown in 10-cm dishes and transfected with 30 mg of pSG5 expression construct. Cells were harvested 48 h after transfection, resuspended in 400 ml buffer A (10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT and protease inhibitor cocktail for mammalian tissues (Sigma P8340) dilution 1:1000) and incubated at 4 8C for 20 min. After vortexing and centrifugation, cell pellets were resuspended in 50 ml of buffer C (20 mM HEPES-KOH (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.2 mM DTT and protease inhibitor cocktail dilution 1:1000), incubated at 4 8C for 20 min, briefly vortexed and centrifuged for 10 min at 4 8C. were annealed (in buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 1 mM DTT, 50 mg/ml BSA) and then Klenow labelled with [ 32 P]dCTP. Labelled probes were separated from unincorporated nucleotides by gel filtration on Sephadex G50 spin columns. Binding reactions contained 3, 6 or 12 mg nuclear extract, 15 mM Tris (pH 7.5), 75 mM NaCl, 1.5 mM EDTA, 0.3% NP-40, 0.8 mg poly(dI-dC), 4 mM spermidine, 4 mM spermine, 1.5 mM DTT and 7.5% glycerol. After incubation on ice for 10 min, 2 £ 10 4 cpm of probe was added and the mixture was incubated at room temperature for 20 min before separation on 5% polyacrylamide=0:5£ TBE gels.
